In contrast, previous studies demonstrated that As2O3 induced apoptosis in two GBM cell lines with different p53 status (T98G-mutated; U-87-wt), and further showed that T98G cells were more sensitive to As2O3 in comparison to U-87 cells [27,68], suggesting the usability of As2O3 as a novel anti-glioma drug despite differential p53 status. The gene discussed is TP53; the disease is central nervous system cancer.